Skip navigation


Transforming the management of cancer with personalized testing

Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for cancer management.

Knowing earlier matters

Each person’s cancer is as unique as their fingerprint. Signatera is a new blood test that is personalized to each patient’s set of tumor mutations and can identify earlier than traditional tools if cancer is still present. Knowing this information can help you have a more informed discussion with your doctor regarding your treatment journey.


How Signatera helps patients through their treatment

Scanxiety is often echoed during patient conferences, forums, and on social media. Living scan to scan creates a situation where patients are unable to make plans outside of months or even weeks. Why let indeterminate scans and unclear biomarkers like CEA be the barrier? Through shared decision making, many patients are working closely with their doctors to incorporate Signatera into their plan to provide additional information needed for confident decision making and to provide patients peace of mind between scans.


Watch Brooks, a young onset CRC patient, discuss her story and experience using Signatera

Signatera is validated in multiple cancer types


I have colorectal cancer

If you have been diagnosed with colorectal cancer, learn more how to identify residual disease and detect relapse sooner


I am on immunotherapy

If you are undergoing immunotherapy and want to know how Signatera can help monitor the effectiveness of your treatment


Is Signatera right for me?

If you have been diagnosed with cancer such as breast, ovarian, lung or melanoma and want to learn more how to identify residual disease and detect relapse sooner

Why Signatera?

Signatera is a blood test used for cancer detection and surveillance. It is personalized for each patient.
A doctor may order Signatera along with routine follow-up exams to determine whether:

  • There are signs of cancer remaining in the body
  • Treatment (e.g., chemotherapy, radiation) is working
  • The cancer is recurring

How Signatera Works: a personalized and tumor informed approach to MRD surveillance


A one-time analysis of both blood and tissue determines your unique set of tumor mutations.


The test is custom-built and personalized for you.


Signatera detects the presence or absence of cancer each time it is ordered as part of your routine follow-up blood tests.

Understanding your Signatera test results

Your test results will either be positive or negative for the presence of tumor DNA in your blood. Your doctor will receive the test report and will be able to discuss your results and answer questions.
IMPORTANT: Negative results may change over time. A negative Signatera result doesn’t guarantee that tumor DNA is not in your blood, or that it will never be detected in the future. This is why ongoing monitoring with the Signatera test in oncology treatment centers over the course of your cancer care, as directed by your doctor, is recommended—for early detection of residual disease
Negative result
A negative result indicates that tumor DNA was not detected in your blood and that you are more likely to remain cancer-free if you were diagnosed with early stage cancer.
If you have metastatic cancer, a negative result may mean that your treatment was able to decrease the amount of cancer cells to undetectable levels, meaning the treatment has been effective.
Positive result
A positive result indicates that tumor DNA has been detected in your blood and means there is higher risk for your cancer returning if you were diagnosed with early-stage cancer. Your doctor may continue to monitor your ctDNA levels to assess your tumor’s response to treatment.

Is Signatera right for you?

We’re here to help you find out